138 related articles for article (PubMed ID: 32038795)
41. Noninvolvement of CYP2E1 in the (omega-1)-hydroxylation of fatty acids in rat kidney microsomes.
Amet Y; Zerilli A; Goasduff T; Dréano Y; Berthou F
Biochem Pharmacol; 1997 Oct; 54(8):947-52. PubMed ID: 9354595
[TBL] [Abstract][Full Text] [Related]
42. Mitochondrial dysfunction by gamma-irradiation accompanies the induction of cytochrome P450 2E1 (CYP2E1) in rat liver.
Chung HC; Kim SH; Lee MG; Cho CK; Kim TH; Lee DH; Kim SG
Toxicology; 2001 Mar; 161(1-2):79-91. PubMed ID: 11295257
[TBL] [Abstract][Full Text] [Related]
43. Immunosuppressive effects of rutaecarpine in female BALB/c mice.
Jeon TW; Jin CH; Lee SK; Jun IH; Kim GH; Lee DJ; Jeong HG; Lee KB; Jahng Y; Jeong TC
Toxicol Lett; 2006 Jul; 164(2):155-66. PubMed ID: 16412592
[TBL] [Abstract][Full Text] [Related]
44. Impaired 6-hydroxychlorzoxazone elimination in patients with kidney disease: Implication for cytochrome P450 2E1 pharmacogenetic studies.
Nolin TD; Gastonguay MR; Bies RR; Matzke GR; Frye RF
Clin Pharmacol Ther; 2003 Dec; 74(6):555-68. PubMed ID: 14663458
[TBL] [Abstract][Full Text] [Related]
45. Oxidative metabolism of the alkaloid rutaecarpine by human cytochrome P450.
Ueng YF; Don MJ; Jan WC; Wang SY; Ho LK; Chen CF
Drug Metab Dispos; 2006 May; 34(5):821-7. PubMed ID: 16501007
[TBL] [Abstract][Full Text] [Related]
46. Chlorzoxazone pharmacokinetics as a marker of hepatic cytochrome P4502E1 in humans.
Mishin VM; Rosman AS; Basu P; Kessova I; Oneta CM; Lieber CS
Am J Gastroenterol; 1998 Nov; 93(11):2154-61. PubMed ID: 9820389
[TBL] [Abstract][Full Text] [Related]
47. In vitro and in vivo metabolic activation and hepatotoxicity of chlorzoxazone mediated by CYP3A.
Sun C; Zhang M; Guan C; Li W; Peng Y; Zheng J
Arch Toxicol; 2024 Apr; 98(4):1095-1110. PubMed ID: 38369618
[TBL] [Abstract][Full Text] [Related]
48. Chlormethiazole inhibition of cytochrome P450 2E1 as assessed by chlorzoxazone hydroxylation in humans.
Gebhardt AC; Lucas D; Ménez JF; Seitz HK
Hepatology; 1997 Oct; 26(4):957-61. PubMed ID: 9328319
[TBL] [Abstract][Full Text] [Related]
49. Induction of NAD(P)H: quinone reductase by rutaecarpine isolated from the fruits of Evodia rutaecarpa in the murine hepatic Hepa-1c1c7 cell line.
Ahn H; Nam JW; Seo EK; Mar W
Planta Med; 2008 Sep; 74(11):1387-90. PubMed ID: 18729042
[TBL] [Abstract][Full Text] [Related]
50. A new class of COX-2 inhibitor, rutaecarpine from Evodia rutaecarpa.
Moon TC; Murakami M; Kudo I; Son KH; Kim HP; Kang SS; Chang HW
Inflamm Res; 1999 Dec; 48(12):621-5. PubMed ID: 10669112
[TBL] [Abstract][Full Text] [Related]
51. Phenotyping of cytochrome P450 2E1 in vitro and in vivo.
Ernstgård L; Johanson G; Karlsson AS; Warholm M
Curr Drug Metab; 2007 Jun; 8(5):493-8. PubMed ID: 17584020
[TBL] [Abstract][Full Text] [Related]
52. Time effect of rutaecarpine on caffeine pharmacokinetics in rats.
Estari RK; Dong J; Chan WK; Park MS; Zhou Z
Biochem Biophys Rep; 2021 Dec; 28():101121. PubMed ID: 34527815
[TBL] [Abstract][Full Text] [Related]
53. Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane.
Kharasch ED; Thummel KE
Anesthesiology; 1993 Oct; 79(4):795-807. PubMed ID: 8214760
[TBL] [Abstract][Full Text] [Related]
54. Metabolic oxidation and toxification of N-methylformamide catalyzed by the cytochrome P450 isoenzyme CYP2E1.
Hyland R; Gescher A; Thummel K; Schiller C; Jheeta P; Mynett K; Smith AW; Mráz J
Mol Pharmacol; 1992 Feb; 41(2):259-66. PubMed ID: 1538706
[TBL] [Abstract][Full Text] [Related]
55. Single-dose disulfiram inhibition of chlorzoxazone metabolism: a clinical probe for P450 2E1.
Kharasch ED; Thummel KE; Mhyre J; Lillibridge JH
Clin Pharmacol Ther; 1993 Jun; 53(6):643-50. PubMed ID: 8513656
[TBL] [Abstract][Full Text] [Related]
56. [Studies on pharmacokinetics of evodiamine and rutaecarpine in rats plasma after oral administration extracts of euodiae fructus].
Bao T; Li Y; Weng X; Yang Q; Zhang Y; Dong Y; Zhu X
Zhongguo Zhong Yao Za Zhi; 2011 Dec; 36(24):3519-22. PubMed ID: 22368870
[TBL] [Abstract][Full Text] [Related]
57. Comprehensive kinetic analysis and influence of reaction components for chlorzoxazone 6-hydroxylation in human liver microsomes with CYP antibodies.
Yamamura Y; Koyama N; Umehara K
Xenobiotica; 2015 Apr; 45(4):353-60. PubMed ID: 25815637
[TBL] [Abstract][Full Text] [Related]
58. Determination of cytochrome P450 2E1 activity in microsomes by thin-layer chromatography using [2-14C]chlorzoxazone.
Zerilli A; Lucas D; Berthou F; Bardou LG; Ménez JF
J Chromatogr B Biomed Appl; 1996 Feb; 677(1):156-60. PubMed ID: 8925089
[TBL] [Abstract][Full Text] [Related]
59. Phase I and phase II metabolite identification of rutaecarpine in freshly isolated hepatocytes from male Sprague-Dawley rats.
Lee DW; Kang Y; Kang MJ; Noh K; Kim JH; Nepal MR; Shakya R; Lee YJ; Jahng Y; Lee S; Kim JA; Jeong TC
Arch Pharm Res; 2017 Aug; 40(8):972-979. PubMed ID: 28799086
[TBL] [Abstract][Full Text] [Related]
60. Evaluation of rat hepatic 2E1 activity in function of age, sex and inducers: choice of an experimental model capable of testing the hepatotoxicity of low molecular weight compounds.
Morel G; Cossec B; Lambert AM; Binet S
Toxicol Lett; 1999 Jun; 106(2-3):171-80. PubMed ID: 10403661
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
